These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31219936)

  • 1. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease.
    Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL
    J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
    Hutsell SQ; Wu M; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A home infliximab infusion program.
    Condino AA; Fidanza S; Hoffenberg EJ
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
    Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
    Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 14. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
    Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
    van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.